IBI311
Phase 3Biologic
Innovent Biologics (Suzhou) Co. Ltd.IBI311 is one of 18 biologic programs targeting Thyroid Eye Disease. It is currently in Phase 3.
1
Indications
9
Total Trials
5
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Thyroid Eye Disease
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Zolymbus
AbbVieApproved
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
TEPEZZA
HHorizon Therapeutics Ireland DAC
Approved
AMG 333
AmgenPhase 2
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
IBI311
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
VRDN-003
VViridian Therapeutics, Inc.
Phase 3
Batoclimab
IImmunovant Sciences GmbH
Phase 3
MHB018A
MMinghui Pharmaceutical (Hangzhou) Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thyroid Eye Disease4 trials
Efficacy and Safety2 trials
Thyroid Associated Ophthalmopathy1 trial
Safety and Efficacy1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI311. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details